Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis - Top-Institutions - MDSpire

Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis

  • By

  • Yu-Pin Huang

  • Hsiao-Jen Chung

  • I-Shen Huang

  • Tzu-Ping Lin

  • Shing-Hwa Lu

  • Eric Y. H. Huang

  • September 2, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Oncology
    • Robotic Surgery
    • Interventional Radiology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Robotic Surgery
    • Oncology
    • Interventional Radiology

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urology
    • Robotic Surgery
    • Oncology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Urology
    • Robotic Surgery
    • Interventional Radiology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Robotic Surgery
    • Oncology

Original Source(s)

Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis

  • by Yu-Pin Huang, Hsiao-Jen Chung, I-Shen Huang, Tzu-Ping Lin, Shing-Hwa Lu, Eric Y. H. Huang

  • September 2, 2025

Related Content

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

Adjuvant Treatment Approaches for Renal Cell Carcinoma: Insights from Historical Challenges and Emerging Possibilities with Immune Checkpoint Inhibitors